CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.0K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $11.0K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $9.0K | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $88.6K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $87.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $164.5K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $165.5K | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $124.4K | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $4.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 29, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.8K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.6K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.4K | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $60.1K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $39.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $113.9K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $120.0K | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $54.0K | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.2K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.00M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($5.49M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($5.29M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($10.14M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $19.21M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($36.33M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($8.48M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($13.66M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($2.66M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($766.1K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.14M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($5.74M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($5.62M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($10.24M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($3.13M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.11M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.13M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($1.11M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($1.18M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($759.7K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.40M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.97M | Mar 14, 2025 |
| FY2023 | Mar 15, 2023 | $5.00M | Mar 22, 2024 |
| FY2023 | Dec 31, 2022 | $6.27M | Mar 22, 2024 |
| FY2022 | Dec 15, 2022 | $5.00M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $109.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $96.6K | Apr 6, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.76M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.24M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.56M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.94M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.96M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.16M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.22M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $1.05M | Apr 6, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.86M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($5.30M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($8.03M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($7.80M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($2.22M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($434.6K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.21M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($1.05M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($889.6K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($445.2K) | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.81M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.67M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $10.72M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $19.19M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $11.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $717.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $530.8K | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $477.2K | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $203.1K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $322.5K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.9K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $327.6K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $371.4K | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.32M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.05M | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $40.52M | Mar 17, 2021 |
| FY2020 | Dec 31, 2019 | $8.60M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $4.47M | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | $2.44M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $480.3K | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.51M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.34M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $10.34M | Mar 14, 2025 |
| FY2024 | Dec 31, 2022 | $15.86M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $10.22M | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | ($39.80M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($8.07M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($3.99M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | ($2.24M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2016 | ($157.8K) | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.59M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($64.59M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($59.10M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($53.81M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($43.67M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($61.89M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($25.57M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($17.08M) | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.43M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($766.6K) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $10.72M | Mar 30, 2022 |
| FY2021 | Dec 31, 2020 | $98.0K | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $88.6K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $304.1K | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | $13.7K | Apr 6, 2020 |
| FY2018 | Dec 31, 2016 | $221.9K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $100 | Mar 29, 2018 |
| FY2016 | Dec 29, 2015 | $0 | Feb 13, 2017 |
| FY2015 | Dec 31, 2014 | $954 | Apr 14, 2016 |
| FY2015 | Dec 31, 2013 | $374 | Apr 14, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $493.3K | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 7 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (62) | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 14, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 5 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (62) | Mar 30, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.70M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 1.75M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 1.37M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 1.41M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 6.34M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 1.54M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 22.49M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | 6.02M | Apr 6, 2020 |
| FY2018 | Dec 31, 2017 | 114.80M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 105.01M | Mar 29, 2018 |